China's Sinopharm COVID-19 Vaccine Has 86% Efficacy, Says UAE

The vaccine is in its late stage clinical trials.

On Wednesday, the health ministry of the United Arab Emirates (UAE) stated Sinopharm's COVID-19 vaccine shows 86% efficiency rates against the coronavirus, as reported by Reuters.

Sinopharm is the name for the China National Pharmaceutical Group, and the analysis comes during its late stage trials of the vaccine in the UAE.

However, no detailed data has yet been shared by either Sinopharm or the UAE.


The UAE stated that it's registered Sinopharm's vaccine, reported the Wall Street Journal.

In September, the vaccine received emergency use approval for certain groups, the first time a vaccine from China received such international clearance. It's one of the top three COVID-19 vaccines being developed in China at the moment, and so far around 1 million people in the country have been inoculated with it.

Sinopharm's COVID-19 vaccine still falls short of other vaccines in terms of efficacy against the coronavirus. Russia's Sputnik V vaccine claims 92% efficiency, Moderna's shows 100% efficiency in certain groups, and Pfizer/BioNTech's vaccine, which the U.K. was the first to claim widespread use, shows a 95% efficiency rate. 

The recent analysis of Sinopharm's vaccine demonstrated that 99% of participants developed antibodies against the virus. This vaccine is based on an inactivated virus.

Bloomberg is keeping a close eye on the world's COVID-19 vaccines, take a look at how Sinopharm is comparing on its graphs.

Follow Us on

Stay on top of the latest engineering news

Just enter your email and we’ll take care of the rest:

By subscribing, you agree to our Terms of Use and Privacy Policy. You may unsubscribe at any time.